Text Size

Erythrocyte and Adipocyte G6PD Activity Levels in Obesity

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
William Richards, University of South Alabama
ClinicalTrials.gov Identifier:
NCT01322035
First received: June 23, 2010
Last updated: January 17, 2013
Last verified: January 2013
History of Changes

June 23, 2010
January 17, 2013
December 2009
December 2013   (final data collection date for primary outcome measure)
Measure erythrocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic Gastric Bypass. [ Time Frame: time of surgery up to 24 months post gastric bypass ] [ Designated as safety issue: No ]
G6PD levels will be measured at the following time intervals: Baseline(prior to gastric bypass surgery), 1 week, 6 weeks, 12 weeks, 6 months, 12 months and 24 months post surgery.
Same as current
Complete list of historical versions of study NCT01322035 on ClinicalTrials.gov Archive Site
  • Measure adipocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass. [ Time Frame: time of surgery up to 12 weeks post gastric bypass ] [ Designated as safety issue: No ]
  • Measure omentum G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass. [ Time Frame: time of surgery up to 12 weeks post gastric bypass ] [ Designated as safety issue: No ]
  • Measure hepatocyte G6PD levels in diabetic vs. non-diabetic morbidly obese patients undergoing laparoscopic gastric bypass. [ Time Frame: time of surgery up to 12 weeks post gastric bypass ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Erythrocyte and Adipocyte G6PD Activity Levels in Obesity
Erythrocyte and Adipocyte G6PD Activity Levels Correlate With Differing Degrees of Dyslipidemia, Insulin Resistance and Obesity

This study compares the improvement of weight, fasting lipid profile (triglycerides, cholesterol, HDL, and LDL) and diabetes after gastric bypass surgery with an improvement in levels of an enzyme called glucose-6-phosphate dehydrogenase (G6PD).

Same as brief summary
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Blood and tissue samples(adipose, omentum and liver biopsies)
Probability Sample

All patients will be morbidly obese and undergo Roux-en-Y Gastric bypass surgery. Both Type 2 diabetic and non-diabetic patients will be accepted into the study.
  • Diabetes
  • Obesity
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
32
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age > 19 years of age and <70 years of age
  • HGA1c<6.0%
  • fasting blood sugar less than 100mg/dL

Exclusion Criteria:

  • Taking antidiabetic medications for other indications
Both
19 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01322035
09.0027
No
William Richards, University of South Alabama
University of South Alabama
Not Provided
Principal Investigator: William O Richards, MD University of South Alabama, Department of Surgery
University of South Alabama
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP